Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

25 years of biologic DMARDs in rheumatology.

Journal article

Feldmann M. et al, (2023), Nat Rev Rheumatol

Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300

Journal article

Williams LM. et al, (2020), Proceedings of the National Academy of Sciences, 202004281 - 202004281

Anti-TNF Therapy.

Journal article

Udalova I. et al, (2016), Microbiol Spectr, 4

Macrophage heterogeneity in the context of rheumatic diseases

Journal article

udalova I. et al, (2016), Nature Reviews Rheumatology

IRF5 controls both acute and chronic inflammation

Journal article

Weiss M. et al, (2015), Proceedings of the National Academy of Sciences of the United States of America, 112, 11001 - 11006

IRF5 controls both acute and chronic inflammation.

Journal article

Weiss M. et al, (2015), Proc Natl Acad Sci U S A, 112, 11001 - 11006

Preclinical target validation using patient-derived cells.

Journal article

Edwards AM. et al, (2015), Nat Rev Drug Discov, 14, 149 - 150

Anti-TNF therapy: past, present and future.

Journal article

Monaco C. et al, (2015), Int Immunol, 27, 55 - 62

Load More